PWMG
NKTR icon

Prestige Wealth Management Group’s Nektar Therapeutics NKTR Stock Holding History

Prestige Wealth Management Group’s Portfolio NKTR Stock Details NKTR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2019
Q1 		– Sell
-1
Closed – – 911
2018
Q4 		$0 Buy
+1
New +$604 ﹤0.01% 1280

Other funds holding NKTR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
Primecap Management
Primecap Management Pasadena, California $127B AUM 44.11% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
O
OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Janus Henderson Group
Janus Henderson Group London, United Kingdom $209B AUM 37.72% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
JP Morgan Chase
JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Prestige Wealth Management Group's NKTR Position: Q1 2019 in Review

Prestige Wealth Management Group sold out of Nektar Therapeutics (NKTR) in Q1 2019, closing a stake of 1 share.

Prestige Wealth Management Group first reported a position in NKTR in Q4 2018 and held it in 1 quarter. The position peaked at $0 in Q4 2018. 350 funds tracked by Wall St. Rank hold NKTR as of Q1 2019.

  • Prestige Wealth Management Group reported no remaining Nektar Therapeutics position as of Q1 2019 after selling out during the quarter.
  • Prestige Wealth Management Group sold 1 Nektar Therapeutics share in Q1 2019.
  • Prestige Wealth Management Group first reported a position in Nektar Therapeutics in Q4 2018 and held it in 1 quarter.
  • Prestige Wealth Management Group's Nektar Therapeutics position peaked at $0 in Q4 2018.
  • 350 funds tracked by Wall St. Rank held Nektar Therapeutics as of Q1 2019.

Based on Prestige Wealth Management Group's 13F filing for Q1 2019, filed 16 Aug 2019.